Top

Published in:

01-03-2011 | Laboratory Investigation - Human/Animal Tissue

Helianthin induces antiproliferative effect on human glioblastoma cells in vitro

Authors: Oana Alexandru, Laura Dragutescu, Ligia Tataranu, Vasile Ciubotaru, Ani Sevastre, Ada Maria Georgescu, Oana Purcaru, Suzana Danoiu, L. Magnus Bäcklund, Anica Dricu

Published in: Journal of Neuro-Oncology | Issue 1/2011

Abstract

A major focus of brain cancer research today is to translate understanding of glioma biology into advances in treatment, by exploring the potential of target therapy. Here we investigated the ability of three compounds belonging to the chemical class of azo dyes (methyl red, methyl yellow, and helianthin) to inhibit glioblastoma (GB) cell growth in vitro. Our results showed that helianthin induced cytotoxicity in two GB cell cultures, cell lines 18 and 38, whereas methyl red and methyl yellow were not cytotoxic. The effect of helianthin on EGFR, IGF-1R, and their common intracellular signaling via PI3-K and ERK1/2 was also analyzed. Treatment with helianthin down-regulated EGFR and IGF-1R activity in both cell lines. Helianthin treatment blocked ERK1/2 phosphorylation without affecting PI3K activity in cell line 18 and reduced both PI3K and ERK1/2 in GB 38 cell line. The cell death was accompanied by degradation of PARP without affecting BCL2 expression in both GB cell cultures. Because of the genetic heterogeneity of malignant gliomas, we tested the effect of helianthin on other two primary GB lines (11 and 15) and two early-passage GB cultures (BT1GB and BT2GB), to assess the general nature of the anti-tumor effect of the drug in GB cells. We found that helianthin treatment induced cell death in all the GB cell cultures analyzed. To our knowledge, this is the first report indicating that helianthin can reduce GB cell growth.

CBTRUS (2006) Primary brain tumors in the United States, 1998–2002. Central Brain Tumor Registry of the United States

Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL (2007) Epidemiology of brain tumors. Neurol Clin 25:867–890 (vii)CrossRefPubMed

CBTRUS (2000–2004.) Primary brain tumors in the United States, 1998–2002. Central Brain Tumor Registry of the United States

Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225CrossRefPubMed

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefPubMed

Zwick E, Bange J, Ullrich A (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8:17–23CrossRefPubMed

Cohen P (2002) Protein kinases—the major drug targets of the twenty-first century? Nat Rev Drug Discov 1:309–315CrossRefPubMed

Hubbard SR (2004) Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 5:464–471CrossRefPubMed

Rendu F, Eldor A, Grelac F, Levy-Toledano S, Levitzki A (1990) Tyrosine kinase blockers: new platelet activation inhibitors. Blood Coagul Fibrinolysis 1:713–716PubMed

10.

Levitzki A (1990) Tyrphostins–potential antiproliferative agents and novel molecular tools. Biochem Pharmacol 40:913–918CrossRefPubMed

11.

Kissau L, Stahl P, Mazitschek R, Giannis A, Waldmann H (2003) Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. J Med Chem 46:2917–2931CrossRefPubMed

12.

Al-Obeidi FA, Lam KS (2000) Development of inhibitors for protein tyrosine kinases. Oncogene 19:5690–5701CrossRefPubMed

13.

Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142CrossRefPubMed

14.

Carapancea M, Alexandru O, Fetea AS, Dragutescu L, Castro J et al (2008) Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J Neurooncol 92(2):137–147CrossRefPubMed

15.

Wen PY, Kesari S, Drappatz J (2006) Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther 6:733–754CrossRefPubMed

16.

Nathoo N, Goldlust S, Vogelbaum MA (2004) Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery 54:1480–1488 (discussion 1488–1489)CrossRefPubMed

17.

Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF et al (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164–2172PubMed

18.

Kurihara M, Ochi A, Tokunaga Y, Kawaguchi T, Niwa M et al (1989) Expression of insulin-like growth factor I (IGF-I) and epidermal growth factor (EGF) receptors in primary non-glial human brain tumors. No To Shinkei 41:1127–1133PubMed

19.

Carapancea M, Cosaceanu D, Budiu R, Kwiecinska A, Tataranu L et al (2007) Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells. J Neurooncol 85:245–254CrossRefPubMed

20.

Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232CrossRefPubMed

21.

Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH et al (1988) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48:2231–2238PubMed

22.

Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1:44–51PubMed

23.

Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89:2965–2969CrossRefPubMed

24.

Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR et al (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84:6899–6903CrossRefPubMed

25.

Agosti RM, Leuthold M, Gullick WJ, Yasargil MG, Wiestler OD (1992) Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme. Virchows Arch A Pathol Anat Histopathol 420:321–325CrossRefPubMed

26.

Schlegel J, Stumm G, Brandle K, Merdes A, Mechtersheimer G et al (1994) Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol 22:201–207CrossRefPubMed

27.

Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN et al (1990) Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 87:4207–4211CrossRefPubMed

28.

Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK et al (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2–7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61:5355–5361PubMed

29.

Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ et al (2002) Novel monoclonal antibody specific for the de2–7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98:398–408CrossRefPubMed

30.

Sugawa N, Yamamoto K, Ueda S, Morita N, Kita M et al (1998) Function of aberrant EGFR in malignant gliomas. Brain Tumor Pathol 15:53–57CrossRefPubMed

31.

Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59–72PubMed

32.

Zumkeller W (1997) The effect of insulin-like growth factors on brain myelination and their potential therapeutic application in myelination disorders. Eur J Paediatr Neurol 1:91–101CrossRefPubMed

33.

Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244CrossRefPubMed

34.

LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137PubMed

35.

Singer CF, Hudelist G, Lamm W, Mueller R, Czerwenka K et al (2004) Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 11:861–869CrossRefPubMed

36.

Glick RP, Lichtor T, Unterman TG (1997) Insulin-like growth factors in central nervous system tumors. J Neurooncol 35:315–325CrossRefPubMed

37.

El-Badry OM, Helman LJ, Chatten J, Steinberg SM, Evans AE et al (1991) Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest 87:648–657CrossRefPubMed

38.

Nordqvist AC, Peyrard M, Pettersson H, Mathiesen T, Collins VP et al (1997) A high ratio of insulin-like growth factor II/insulin-like growth factor binding protein 2 messenger RNA as a marker for anaplasia in meningiomas. Cancer Res 57:2611–2614PubMed

39.

Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M (1992) Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 50:215–222CrossRefPubMed

40.

Gammeltoft S, Ballotti R, Kowalski A, Westermark B, Van Obberghen E (1988) Expression of two types of receptor for insulin-like growth factors in human malignant glioma. Cancer Res 48:1233–1237PubMed

41.

Melino G, Stephanou A, Annicchiarico-Petruzzelli M, Finazzi-Agro A, Knight RA et al (1992) IGF-II mRNA expression in LI human glioblastoma cell line parallels cell growth. Neurosci Lett 144:25–28CrossRefPubMed

42.

Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259:94–97CrossRefPubMed

43.

Morford LA, Boghaert ER, Brooks WH, Roszman TL (1997) Insulin-like growth factors (IGF) enhance three-dimensional (3D) growth of human glioblastomas. Cancer Lett 115:81–90CrossRefPubMed

44.

Merrill MJ, Edwards NA (1990) Insulin-like growth factor-I receptors in human glial tumors. J Clin Endocrinol Metab 71:199–209CrossRefPubMed

45.

Resnicoff M, Li W, Basak S, Herlyn D, Baserga R et al (1996) Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother 42:64–68CrossRefPubMed

46.

Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D et al (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218–2222PubMed

47.

Cosaceanu D, Carapancea M, Castro J, Ekedahl J, Kanter L et al (2005) Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett 222:173–181CrossRefPubMed

48.

Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M et al (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19:2189–2200PubMed

49.

Mehta K, Pantazis P, McQueen T, Aggarwal BB (1997) Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 8:470–481CrossRefPubMed

50.

Hanif R, Qiao L, Shiff SJ, Rigas B (1997) Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med 130:576–584CrossRefPubMed

51.

Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB (2001) Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20:7597–7609CrossRefPubMed

52.

Seewald MJ, Schlager JJ, Olsen RA, Melder DC, Powis G (1989) High molecular weight dextran sulfate inhibits intracellular Ca2+ release and decreases growth factor-induced increases in intracellular free Ca2+ in Swiss 3T3 fibroblasts. Cancer Commun 1:151–156PubMed

53.

Powis G, Seewald MJ, Melder D, Hoke M, Gratas C et al (1992) Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin. Cancer Chemother Pharmacol 31:223–228CrossRefPubMed

54.

Chung KT, Fulk GE, Andrews AW (1978) The mutagenicity of methyl orange and metabolites produced by intestinal anaerobes. Mutat Res 58:375–379CrossRefPubMed

55.

Chung KT (1983) The significance of azo-reduction in the mutagenesis and carcinogenesis of azo dyes. Mutat Res 114:269–281PubMed

56.

Brown MADSC (1993) Predicting azo dye toxicity. Crit Rev Environ Sci Technol 23:249–324CrossRef

57.

Ponten J, Westermark B (1978) Properties of human malignant glioma cells in vitro. Med Biol 56:184–193PubMed

58.

Hagerstrand D, Hesselager G, Achterberg S, Wickenberg Bolin U, Kowanetz M et al (2006) Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 25:4913–4922CrossRefPubMed

59.

Zee Vd (2002) Anaerobic azo dye reduction

60.

Akerfeldt S, Westin G, Jansson T (1971) Aromatic sulfonic acids as viral inhibitors. Structure-activity study using rhino, adeno 3, herpes simplex, and influenza viruses. J Med Chem 14:595–600CrossRefPubMed

61.

Thorne HV, Clarke GF (1983) Inactivation of measles and herpes simplex viruses by trypan blue. J Gen Virol 64(Pt 6):1365–1368CrossRefPubMed

62.

Carlberg M, Dricu A, Blegen H, Kass GE, Orrenius S et al (1996) Short exposures to tunicamycin induce apoptosis in SV40-transformed but not in normal human fibroblasts. Carcinogenesis 17:2589–2596CrossRefPubMed

63.

Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R et al (2007) Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 26:2423–2434CrossRefPubMed

64.

Gautam J, Schott H (1994) Interaction of anionic compounds with gelatin. I: Binding studies. J Pharm Sci 83:922–930CrossRefPubMed

65.

Roterman I, No KT, Piekarska B, Kaszuba J, Pawlicki R et al (1993) Bis azo dyes—studies on the mechanism of complex formation with IgG modulated by heating or antigen binding. J Physiol Pharmacol 44:213–232PubMed

66.

Katz M, Amit I, Yarden Y (2007) Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta 1773:1161–1176CrossRefPubMed

67.

Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657CrossRefPubMed

68.

Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J et al (2005) Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205:145–153CrossRefPubMed

69.

Henson ES, Gibson SB (2006) Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 18:2089–2097CrossRefPubMed

70.

Ramos JW (2008) The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 40:2707–2719CrossRefPubMed

71.

Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K (1996) Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56:4743–4748PubMed

72.

Smyth MJ, Perry DK, Zhang J, Poirier GG, Hannun YA et al (1996) prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Biochem J 316(Pt 1):25–28PubMed

Title: Helianthin induces antiproliferative effect on human glioblastoma cells in vitro
Authors: Oana Alexandru
Laura Dragutescu
Ligia Tataranu
Vasile Ciubotaru
Ani Sevastre
Ada Maria Georgescu
Oana Purcaru
Suzana Danoiu
L. Magnus Bäcklund
Anica Dricu
Publication date: 01-03-2011
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2011
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0285-7

At a glance: The STEP trials

Springer Medicine

Helianthin induces antiproliferative effect on human glioblastoma cells in vitro

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image

Clinical characteristics and treatment of ectopic meningiomas

Let-7 microRNA inhibits the proliferation of human glioblastoma cells

Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions

Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma

Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53